Mayo Clinic, the world’s leading medical center, discovered bone deterioration is yet another complication of diabetes. The discovery was enabled by a new medical device, OsteoProbe®, developed by Active Life Scientific, Inc. in Santa Barbara, California.
OsteoProbe® is designed to measure the material properties of bone as a signature of bone strength, and as a target for new treatments and disease prevention. A growing body of scientific evidence is attracting an A-list of global customers and collaborators to the medical value of the company’s novel technology.
“We congratulate Dr. Khosla and his top-notch team for this vital contribution to medical knowledge,” says Davis Brimer, Active Life Chief Executive Officer. “These important findings further validate the significance of material properties to bone strength.”
“This is the first demonstration – using direct measurement of bone strength in the body – of compromised bone material in patients with type 2 diabetes,” says Sundeep Khosla, M.D., Mayo Clinic endocrinologist, senior author of the study.
It is known that a patient with diabetes has a higher fracture risk than a non-diabetic, what is not known is why. The gold-standard method for diagnosing fracture risk is a bone density scan to determine how much bone there is, however that method is ineffective because diabetics have the same bone density as non-diabetics. The study suggests a deterioration of bone material properties may indicate a greater risk of fracture.